# KLRS catalysts: Kalaris Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/klrs/catalysts

> Kalaris Therapeutics, Inc. (KLRS) has 2 upcoming catalysts. The next is the TH103 interim data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for KLRS?

Kalaris Therapeutics, Inc. (KLRS) has 2 upcoming catalysts. The next is the TH103 interim data readout, 1H 2027. SEC Form 8-K: "Study results will inform dose selection for potential future Phase 3 trials of TH103, and the Company remains on-track to share initial data from the Phase 1b/2 study in the first half of 2027." [Calendar and source filings](https://sec-api.dev/companies/klrs/catalysts)

Source: SEC Form 8-K, accession 0001193125-26-306737, https://www.sec.gov/Archives/edgar/data/1754068/000119312526306737/d125006d8k.htm (retrieved 2026-11-12). Last confirmed 2026-07-17. Cite: https://sec-api.dev/companies/klrs/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Kalaris Therapeutics, Inc. |
| Ticker | KLRS (Nasdaq) |
| SEC CIK | 1754068 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/klrs |

## Cash runway

Cash $82.9M as of 2026-09-30; quarterly burn $10.6M; about 23.5 months of runway at that rate (XBRL company facts, accession 0001193125-26-455378).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| January 5, 2023 | [TH103 FDA approval](https://sec-api.dev/pdufa/th103) | KLRS |  | completed, approved | "On January 5, 2023, the FDA approved Floridas plan for Canadian importation." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex992.htm)) |
| Jun 2024 | [TH103 trial start](https://sec-api.dev/pdufa/th103) | KLRS |  | completed | "CDMO, CRO and other third-party preclinical studies, clinical trials and consulting costs increased by $1.4 million as we initiated our Phase 1a clinical trial in TH103 in June 2024 and our Phase 1b/2 clinical trial in the third quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1754068/000119312526219328/klrs-20260331.htm)) |
| Aug 2024 | [TH103 trial start](https://sec-api.dev/pdufa/th103) | KLRS |  | completed | "We dosed the first patient in our Phase 1a clinical trial of TH103 in August 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1754068/000119312525277464/klrs-20250930.htm)) |
| December 31, 2024 | [TH103 trial start](https://sec-api.dev/pdufa/th103) | KLRS |  | completed | "CRO expenses increased by $2.9 million during the year ended December 31, 2024 as Kalaris initiated its Phase 1 clinical trial in June 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex994.htm)) |
| March 18, 2025 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Changes in estimates are reflected in reported results for the period in which they become known." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex994.htm)) |
| May 14, 2025 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525119408/d916904dex991.htm)) |
| Q3 2025 | [TH103 interim data readout](https://sec-api.dev/pdufa/th103) | KLRS |  | scheduled | "Age-related Macular Degeneration (nAMD), a leading cause of blindness in the United States and Europe that affected an estimated 1.6 million adults in the United States in 2023, and Kalaris expects to report initial clinical data from Part 1 of the Phase 1 clinical trial in the third quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex994.htm)) |
| July 15, 2025 | [Kalaris Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | scheduled | "As of July 15, 2025, there has been at least one report in which the FDA failed to meet a PDUFA goal date for approval of an NDA due to heavy workload and limited resources." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1754068/000095017025107979/klrs-20250630.htm)) |
| August 13, 2025 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports Second Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/d913327dex991.htm)) |
| Q4 2025 | [TH103 interim data readout](https://sec-api.dev/pdufa/th103) | KLRS | neovascular Age-related Macular Degeneration | scheduled | "Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525179464/d913327dex991.htm)) |
| November 12, 2025 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525276060/d70447dex991.htm)) |
| December 17, 2025 | [TH103 interim data readout](https://sec-api.dev/pdufa/th103) | KLRS | neovascular Age-related Macular Degeneration | completed, positive | "Therapeutics, Inc. (NASDAQ: KLRS), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced positive initial data from its Phase 1a single ascending dose (SAD) trial of TH103, a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor, in treatment-na&iuml;ve patients with neovascular age-related macular degeneration (nAMD)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525322950/d25416dex991.htm)) |
| 2026 | [OLN324 trial start](https://sec-api.dev/pdufa/oln324) | KLRS |  | scheduled | "Ollin is investigating OLN324, a VEGF/Ang2 bispecific antibody, in a Phase 2 trial in DME and nAMD and has indicated the goal of commencing Phase 3 trials in 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1754068/000119312526110659/klrs-20251231.htm)) |
| March 17, 2026 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/d124100dex991.htm)) |
| May 12, 2026 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312526218240/d24879dex991.htm)) |
| 2H 2026 | [TH103 interim data readout](https://sec-api.dev/pdufa/th103) | KLRS |  | scheduled | "Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for potential Phase 3 development program; initial clinical data expected in 2H 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525276060/d70447dex991.htm)) |
| August 11, 2026 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312526343477/d114296dex991.htm)) |
| Q4 2026 | [TH103 trial start](https://sec-api.dev/pdufa/th103) | KLRS |  | scheduled | "The combined companys cash and cash equivalents of approximately $100 million as of the closing date is expected to be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of 2026. We are delighted to close this transaction, which we expect will provide us with the financial resources to continue development of TH103 beyond the initiation of our planned Phase 2 clinical trial, said Andrew Oxtoby, CEO of Kalaris Therapeutics." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312525056725/d925335dex991.htm)) |
| November 10, 2026 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312526454454/d164715dex991.htm)) |
| 1H 2027 | [TH103 interim data readout](https://sec-api.dev/pdufa/th103) | KLRS |  | scheduled | "Study results will inform dose selection for potential future Phase 3 trials of TH103, and the Company remains on-track to share initial data from the Phase 1b/2 study in the first half of 2027." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1754068/000119312526306737/d125006d8k.htm)) |
| late 2027 | [TH103 trial start](https://sec-api.dev/pdufa/th103) | KLRS |  | scheduled | "Intend to initiate Phase 3 clinical trials by year-end 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/d124100dex991.htm)) |

## Drugs

- [OLN324](https://sec-api.dev/pdufa/oln324): 
- [TH103](https://sec-api.dev/pdufa/th103): neovascular age-related macular degeneration, neovascular and exudative diseases of the retina

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/klrs/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "KLRS catalysts: Kalaris Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/klrs/catalysts

```bibtex
@misc{secapidev_companies_klrs_catalysts_20261116,
  title        = {KLRS catalysts: Kalaris Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/klrs/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_klrs_catalysts_20261116","title":"KLRS catalysts: Kalaris Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/klrs/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
